Drug Safety Information for KADIAN (Morphine sulfate)

REMS for MORPHINE SULFATE (MORPHINE SULFATE) Rx Drug: FDA Link

Shared FDA Risk Evaluation and Mitigation Strategy

Safety-related Labeling Changes for MORPHINE SULFATE (MORPHINE SULFATE) Rx Drug: FDA Link

Safety-related Labeling Changes for KADIAN (MORPHINE SULFATE) Rx Drug: FDA Link

Safety-related Labeling Changes for EMBEDA (MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE) Rx Drug: FDA Link

Safety-related Labeling Changes for MORPHABOND (MORPHINE SULFATE) Rx Drug: FDA Link

Safety-related Labeling Changes for ARYMO ER (MORPHINE SULFATE) Discontinued Drug: FDA Link

Safety-related Labeling Changes for DURAMORPH PF (MORPHINE SULFATE) Rx Drug: FDA Link

Safety-related Labeling Changes for MS CONTIN (MORPHINE SULFATE) Rx Drug: FDA Link

Required post-approval safety study:

A prospective, observational study designed to quantify the serious risks of misuse, abuse, and addiction associated with long-term use of opioid analgesics for management of chronic pain among patients prescribed ER/LA opioid analgesics. This study must address at a minimum the following specific objectives: a. Estimate the incidence of misuse, abuse, and addiction associated with long-term use of opioid analgesics for chronic pain. Examine the effect of product/formulation, dose and duration of opioid use, prescriber specialty, indication, and other clinical factors (e.g., concomitant psychotropic medications, personal or family history of substance abuse, history of psychiatric illness) on the risk of misuse, abuse, and addiction. b. Evaluate and quantify other risk factors for misuse, abuse, and addiction associated with long-term use of opioid analgesics for chronic pain, including but not limited to the following: demographic factors, psychosocial/behavioral factors, medical factors, and genetic factors. Identify confounders and effect modifiers of individual risk factor/outcome relationships. Due Date: 2020-03-31

Original FDA Drug Approval Date for KADIAN: 1996-07-03

Adverse Drug Reactions for KADIAN* (Morphine sulfate)

These charts and graphs are based on reports received through the FDA Adverse Event Reporting System (FAERS) program (see below).

Top 20 Adverse Effects Associated with KADIAN
(reported in FDA Medwatch/FAERS Reports)

  Side Effect # of FDA Reports
1Nausea*3589
2Pain*3424
3Death3169
4Vomiting3048
5Dyspnoea2441
6Drug abuse2402
7Drug ineffective*2311
8Toxicity to various agents2259
9Drug hypersensitivity2062
10Diarrhoea1962
11Fatigue1946
12Somnolence*1935
13Pyrexia1857
14Hypotension1775
15Pneumonia1749
16Confusional state1712
17Overdose1700
18Asthenia1636
19Headache*1556
20Constipation*1498

* This side effect also appears in "Top 10 Side Effects of KADIAN " in the drug's Review Summary based on AskaPatient reviews.

Top 10 Reasons for Taking KADIAN
(associated with FDA Medwatch/FAERS Reports)

Reason # of FDA Reports
1Pain*36512
2Product used for unknown indication31011
3Back pain*4902
4Cancer pain3241
5Analgesic therapy2425
6Breakthrough pain1529
7Procedural pain1438
8Pain management1126
9Abdominal pain*1112
10Arthralgia1016

*Also a top-10 reason in AskaPatient Review Summary.


Types of Adverse Events for KADIAN

Total Reports Filed with FDA: 270458


Number of FDA Adverse Event Reports by Patient Age for KADIAN

Total Reports Filed with FDA: 270458*


* Reports for drugs with the same active ingredients have been aggregated in this analysis: Morphine sulfate (Morfina, Duramorph, Morphine sulfateer, Morphine, Infumorph 200, Infumorph 500, Astramorph, Infumorph, Kadian er, Morph, Astramorph pf, Duramorph pf, Depodur, Morphine sulfate, Avinza, Ms contin, Kadian, Oramorph sr)

Charts are based on 270458 reports filed with the FDA between 2004 and June 2015.

Adverse Event Reports are submitted to the FDA by pharmaceutical companies (mandatory reporting is required by manufacturers, distributors, or importers), health care providers such as doctors (voluntary reporting), and by patients themselves (voluntary reporting). More Information on FDA MedWatch (FDA Safety Information and Adverse Event Reporting Program)Voluntary reporting takes place under the FDA's MedWatch program, where health care professionals and consumers submit reports to FDA when they find a problem with a drug, medical device, biologic, or other FDA-regulated product. An adverse event is any undesirable experience or extreme side effect associated with the use of a medical product. Adverse events include: death, life threatening event, hospitalization, disability or permanent damage, congenital anomaly or birth defect, medical product use requiring a surgical or other intervention, or other serious medical situation believed to be caused by the drug.

Click to go back to search results and KADIAN Reviews and Review Summary .

Historical Analytics of FDA Adverse Event Reports Provided by Druginformer.com. FDA Drug Safety Information, including safety-related labeling updates, required post-approval safety studies, risk evaluation management strategies (REMS), alerts, and recalls are compiled by AskaPatient.com from the U.S. Food and Drug Administration.